{"title":"晚期非小细胞肺癌免疫联合治疗双预测标志物的队列研究","authors":"Maike Zheng, Mingming Hu, Yanxia Liu, Xiaomi Li, Guirong Wang, Tongmei Zhang, Yan Zhao","doi":"10.1177/11772719251319641","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) hold a great promise in treatment of non-small cell lung cancer (NSCLC), while only a portion of patients benefited from the treatment, and others could not achieve optimal therapeutic effects from initial immunotherapy, even for those patients with PD-L1 (Programed cell death ligand 1) tested positive. However, the clinical markers for the selection of patients who will benefit from ICIs combination treatment beforehand are largely unknown.</p><p><strong>Objectives: </strong>The purpose of this study was to explore the non-invasive biomarkers that can predict the efficacy of immune combination therapy in advanced/metastatic NSCLC patients.</p><p><strong>Design: </strong>This study employed a retrospective cohort design to analyze dual predictive biomarkers in advanced non-small cell lung cancer (NSCLC) patients with immune combination therapy.</p><p><strong>Method: </strong>An analysis was conducted on baseline information of 144 patients with advanced/metastatic NSCLC who received ICIs treatment from the November of 2018 to the January of 2023 in Beijing Chest Hospital. We established a scoring group chart to make quantitative prediction for overall survival (OS) and progression-free survival (PFS) based on 4 variables, and set up the nomogram model as well as Decision curve analysis (DCA) to assess clinical benefits of ICIs combination in treatment of patients with advanced/metastatic NSCLC.</p><p><strong>Results: </strong>We found that serum globulin (GLB) >26.6 (g/L) (HR = 1.865, <i>P</i> = .002), absolute neutrophil counts (ANC) (10<sup>9</sup>/L) > 5 (HR = 2.146, <i>P</i> < .001), and bone metastasis (HR = 2.148, <i>P</i> < .001) were independent factors affecting the PFS of NSCLC patients. GLB > 26.6 (g/L) (HR = 1.741, <i>P</i> = .018), ANC (10<sup>9</sup>/L) >5 (HR = 1.807, <i>P</i> = .008), bone metastasis (HR = 1.651, <i>P</i> = .002), and PD-L1 Negative (HR = 2.432, <i>P</i> = .032) were independent factors affecting the OS of NSCLC patients. Same variables and cut-off value have good predictive efficacy in both PFS and OS.</p><p><strong>Conclusion: </strong>In patients with advanced/metastatic NSCLC receiving ICIs combination treatment, the GLB, ANC, bone metastasis, and PD-L1 may serve as useful predictive markers for the prognosis of NSCLC patients with ICIs combination treatment.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251319641"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829304/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer.\",\"authors\":\"Maike Zheng, Mingming Hu, Yanxia Liu, Xiaomi Li, Guirong Wang, Tongmei Zhang, Yan Zhao\",\"doi\":\"10.1177/11772719251319641\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) hold a great promise in treatment of non-small cell lung cancer (NSCLC), while only a portion of patients benefited from the treatment, and others could not achieve optimal therapeutic effects from initial immunotherapy, even for those patients with PD-L1 (Programed cell death ligand 1) tested positive. However, the clinical markers for the selection of patients who will benefit from ICIs combination treatment beforehand are largely unknown.</p><p><strong>Objectives: </strong>The purpose of this study was to explore the non-invasive biomarkers that can predict the efficacy of immune combination therapy in advanced/metastatic NSCLC patients.</p><p><strong>Design: </strong>This study employed a retrospective cohort design to analyze dual predictive biomarkers in advanced non-small cell lung cancer (NSCLC) patients with immune combination therapy.</p><p><strong>Method: </strong>An analysis was conducted on baseline information of 144 patients with advanced/metastatic NSCLC who received ICIs treatment from the November of 2018 to the January of 2023 in Beijing Chest Hospital. We established a scoring group chart to make quantitative prediction for overall survival (OS) and progression-free survival (PFS) based on 4 variables, and set up the nomogram model as well as Decision curve analysis (DCA) to assess clinical benefits of ICIs combination in treatment of patients with advanced/metastatic NSCLC.</p><p><strong>Results: </strong>We found that serum globulin (GLB) >26.6 (g/L) (HR = 1.865, <i>P</i> = .002), absolute neutrophil counts (ANC) (10<sup>9</sup>/L) > 5 (HR = 2.146, <i>P</i> < .001), and bone metastasis (HR = 2.148, <i>P</i> < .001) were independent factors affecting the PFS of NSCLC patients. GLB > 26.6 (g/L) (HR = 1.741, <i>P</i> = .018), ANC (10<sup>9</sup>/L) >5 (HR = 1.807, <i>P</i> = .008), bone metastasis (HR = 1.651, <i>P</i> = .002), and PD-L1 Negative (HR = 2.432, <i>P</i> = .032) were independent factors affecting the OS of NSCLC patients. Same variables and cut-off value have good predictive efficacy in both PFS and OS.</p><p><strong>Conclusion: </strong>In patients with advanced/metastatic NSCLC receiving ICIs combination treatment, the GLB, ANC, bone metastasis, and PD-L1 may serve as useful predictive markers for the prognosis of NSCLC patients with ICIs combination treatment.</p>\",\"PeriodicalId\":47060,\"journal\":{\"name\":\"Biomarker Insights\",\"volume\":\"20 \",\"pages\":\"11772719251319641\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829304/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarker Insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11772719251319641\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11772719251319641","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：免疫检查点抑制剂（ICIs）在治疗非小细胞肺癌（NSCLC）方面具有很大的前景，但只有一部分患者从治疗中受益，而其他患者无法从初始免疫治疗中获得最佳治疗效果，即使是那些PD-L1（程序性细胞死亡配体1）检测阳性的患者。然而，选择哪些患者将受益于ICIs联合治疗的临床指标在很大程度上是未知的。目的：本研究的目的是探索可以预测晚期/转移性NSCLC患者免疫联合治疗疗效的非侵入性生物标志物。设计：本研究采用回顾性队列设计，分析免疫联合治疗的晚期非小细胞肺癌（NSCLC）患者的双重预测生物标志物。方法：对2018年11月至2023年1月北京胸科医院144例接受ICIs治疗的晚期/转移性NSCLC患者的基线信息进行分析。建立评分组图，基于4个变量对总生存期（OS）和无进展生存期（PFS）进行定量预测，建立nomogram模型和Decision curve analysis (DCA)，评估ICIs联合治疗晚期/转移性NSCLC的临床获益。结果：我们发现血清球蛋白(GLB) >26.6 (g/L) （HR = 1.865, P = 0.002）、绝对中性粒细胞计数（ANC） (109/L) >5 (HR = 2.146, P = 26.6 (g/L) （HR = 1.741, P = 0.018）、ANC (109/L) >5 （HR = 1.807, P = 0.008）、骨转移（HR = 1.651, P = 0.002）、PD-L1阴性（HR = 2.432, P = 0.032）是影响NSCLC患者OS的独立因素。相同的变量和截止值对PFS和OS均有较好的预测效果。结论：在接受ICIs联合治疗的晚期/转移性NSCLC患者中，GLB、ANC、骨转移和PD-L1可作为ICIs联合治疗NSCLC患者预后的有用预测指标。
A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer.
Background: Immune checkpoint inhibitors (ICIs) hold a great promise in treatment of non-small cell lung cancer (NSCLC), while only a portion of patients benefited from the treatment, and others could not achieve optimal therapeutic effects from initial immunotherapy, even for those patients with PD-L1 (Programed cell death ligand 1) tested positive. However, the clinical markers for the selection of patients who will benefit from ICIs combination treatment beforehand are largely unknown.
Objectives: The purpose of this study was to explore the non-invasive biomarkers that can predict the efficacy of immune combination therapy in advanced/metastatic NSCLC patients.
Design: This study employed a retrospective cohort design to analyze dual predictive biomarkers in advanced non-small cell lung cancer (NSCLC) patients with immune combination therapy.
Method: An analysis was conducted on baseline information of 144 patients with advanced/metastatic NSCLC who received ICIs treatment from the November of 2018 to the January of 2023 in Beijing Chest Hospital. We established a scoring group chart to make quantitative prediction for overall survival (OS) and progression-free survival (PFS) based on 4 variables, and set up the nomogram model as well as Decision curve analysis (DCA) to assess clinical benefits of ICIs combination in treatment of patients with advanced/metastatic NSCLC.
Results: We found that serum globulin (GLB) >26.6 (g/L) (HR = 1.865, P = .002), absolute neutrophil counts (ANC) (109/L) > 5 (HR = 2.146, P < .001), and bone metastasis (HR = 2.148, P < .001) were independent factors affecting the PFS of NSCLC patients. GLB > 26.6 (g/L) (HR = 1.741, P = .018), ANC (109/L) >5 (HR = 1.807, P = .008), bone metastasis (HR = 1.651, P = .002), and PD-L1 Negative (HR = 2.432, P = .032) were independent factors affecting the OS of NSCLC patients. Same variables and cut-off value have good predictive efficacy in both PFS and OS.
Conclusion: In patients with advanced/metastatic NSCLC receiving ICIs combination treatment, the GLB, ANC, bone metastasis, and PD-L1 may serve as useful predictive markers for the prognosis of NSCLC patients with ICIs combination treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
